PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

• Status: Unknown status
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: GE Healthcare; National Cancer Institute (NCI)
• Treatments: Deoxyglucose; Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Patients with newly diagnosed AML or acute promyelocytic leukemia (APL)

• Women of child bearing potential with negative pregnancy test documented

Exclusion Criteria:

• Patients with contraindications to MR

• Patients with a creatinine clearance less than 60

• Patients with a known allergy to MR contrast agents

• Uncontrollable claustrophobia

• Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or cytarabine more than 1 g per square meter

• Patients with secondary or relapsed AML or APL should be excluded

• Patients with known extramedullary leukemia

• Positive pregnancy test

• Greater than 400 pounds in weight

• Patients with uncontrolled diabetes